Documente Academic
Documente Profesional
Documente Cultură
Dr Costescu Daniela
Caz Clinic
• Pacienta - B.M
• vârstă 57 ani
• sex F
• mediu urban
• fumatoare
• Pensionata medical, gr.II - invaliditate
Pacienta: BM, 57 ani Motivele prezentării
Durere precordiala
- Declansata in urma unei situatii conflictuale.
- Caracteristicile durerii: iradiaza in umarul si bratul stang,
are o durata de 1-3 minute
cedeaza la repaus si nitroglicerina sublingual,
este insotita de transpiratii, oboseala, anxietate
Antecedente heredocolaterale:
• Mama – hipertensiva in tratament
• Tata - IMA la 56 ani.
Pacienta: BM, 57 ani
Examen clinic
H 1.65 m
G 85 kg
Indice masa corporala – 32 kg/m2,
Tesut celular SC – în exces reprezentat
Aparat cardio-vascular: zgomote cardiace ritmice
AV 96 bpm
TA 170/95 mmHg
Hb – 13g/dl,
Ht 40%,
Ac. Uric – 4,7 mg/dl,
Creatinina 0.7 mg/dl,
Uree 23 mg/dl,
Glicemie 97 mg/dl,
Colesterol total 321 mg/dl,
HDL – 46 mg/dl,
LDL 210.8 mg/dl,
Trigliceride 321 mg/dl,
TGO – 30 U/dl,
TGP - 64 U/dl
Pacienta: BM, 57 ani Examen paraclinic
Diagnosticul pozitiv
• Angina pectorala stabila,
• HT st. II neglijata terapeutic,
• Dislipidemie mixta,
• Obezitate gr.I,
• Tulburare anxios-depresiva
MF si Identificarea cat mai precoce a CAD
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2019) 00, 1-71
SCORE 2 ESC Cardiovascular risk collaboration
Figure 2 Risk regions based on standardised cardiovascular disease mortality rates. Countries were grouped into four
risk regions according to their most recently reported WHO age- and sex-standardized overall CVD mortality rates per
100,000 population (ICD chapters 9, I00-I99). The four groupings were: low risk (_300 CVD deaths per 100,000).
Figure 3 SCORE2 charts for estimation of CVD risk in four European risk regions.
Prevalenta obstructiei coronariene la pacientii cu suspiciune de BCI
Probabilitatea clinica pretest pentru boala coronariana obstructiva
la 15 815 pacienti simptomatici in functie de varsta, sex si natura simptomelor Poate fi
Doar singurul
10-15% simptom
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2019) 00, 1-71
Abordare diagnostica
Evaluarea anatomiei coronariene Evaluarea ischemiei
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesEuropean Heart Journal (2019); doi:10.1093/eurheartj/ehz425
Perindopril 10 mg – 1 cpr/zi Modificarea stilului de viata
Bisoprolol – 5 mg/zi - exercitii fizice min. 30 min/zilnic,
Acid acetilsalicilic 75 mg/zi - se renunta la fumat,
Rosuvastatina – 20 mg/zi - reducerea consumului de sare,
Preductal MR – 35 mg/ 2cpr/zi - scadere ponderala,
- regim alimentar hipolipidic.
Nitroglicerina – la nevoie
• Pacienta a fost internata in sectia
de cardiologie
EKG – BRS cu unde RS V5-V6 cu subdenivelare ST in V5-V6 ca
si tulburari de repolarizare secundare
Ecocardiografie - ventricul stang 50/38 mm, SIV - 9.5 mm, AS- 32 mm,
FE – 50% prin miscare dischinetica de SIV, valva mitrala normala,
cavitati drepte ne dilatate, aorta de calibru normal, pericard liber.
BCI, boala cardiaca ischemica; IC, insuficienta cardiaca; SCA, sindrom coronarian acut
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2019) 00, 1-71
Mecanismele implicate in ischemia miocardica
Disfunctie microvasculara
Obstructie coronariana Spasm
coronariana coronarian
1. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2019) 00, 1-71; 2. Kaski et al Circulation. 2018;138:1463–1480.;
3. Ford TJ, Berry C. Heart 2020;106:387–398.
Impactului bolii cardiace ischemice asupra activitatii cotidiene:
perceptia pacientilor
1. Ambrosio G et al. Angiology. 2019:70(5):397-406; 2. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2019) 00, 1-71
Pacientii cu boala cardiaca ischemica si limitari severe ale capacitatii de
efort au un risc de mortalitate x 4 mai mare
fata de cei cu limitari minime
Supravietuirea (%) Riscul de mortalitate al pacientilor cu BCI in
functie de limitarile fizice comparativ cu cei
cu limitare minima, evaluat dupa 2 ani
Timp (luni)
Tratamentul
hemodinamic
4 * 4,4 * *
*
3
*
2,9 * *
2 *p<0.05
* vs includere
*
*
n = 221 pacienti cu angina
1 pectorala stabila
0
includere n=221
2 sapt 2 luni
bisoprolol + Preductal MR
20 Preductal MR
ISDN
30
-76% -79%
40
50
60
70
80
P<0.0001 P<0.0001
Complementaritate cu betablocantele
4 4.6
3 3.5
3.1 P <0.01
2
1.7*
1 n=94 de pacienţi post-revascularizare
0
M0
La includere 3 months
Dupa 3 luni
Metoprolol+
Metoprolol + placebo Metoprolol+
Metoprolol + VASTAREL
placebo PREDUCTAL
66months
luni 669.1 *
44months
luni 604.7*
22months
luni 512.4 *
*
2 săptămâni
2 weeks 390.4 *
Baseline 357,9
Includere
100 200 300 400 500 600 700
Preductal MR
n = 75 pacienti cu angina pectorala stabila, < 1 an *p <0,001 vs vizita anterioara
480
*
460
+ 66 sec
*
440
n=426 pacienți cu angina
pectorala de efort
420
12 saptamani
* p<0,01 fata de includere
** p<0,01 diferenta intre
400
grupuri la 12 luni
380
metoprolol + placebo metoprolol + Preductal
1. J Peteiro et al. European Heart Journal - Cardiovascular Imaging, Volume 22, Issue Supplement_1, January 2021, jeaa356.196,
https://doi.org/10.1093/ehjci/jeaa356.196. 2. . Glezer M et al, Cardiol Ther, 2020 ; doi: 10.1007/s40119-020-00202-6
Reduce severitatea anginei pectorale
conform clasificarii CCS
Încadrarea în Clasele CCS la includere și finalul celor 6 luni de evaluare
600 563
500 472
La includere După 6 luni
400
300 272
233
x6
200 x4
100 45 60
4 0
0
Clasa CCS I Clasa CCS II Clasa CCS III Clasa CCS IV
Baseline 2 weeks
2 luni 2 months 4 months 6 months
Includere 2 săptămâni 4 luni 6 luni
Preductal MR
• Evolutie favorabila:
ü reducerea episoadelor anginoase
ü cresterea tolerantei la efort,
ü scadere ponderala 4 kg,
ü TA 130/75 mmHg,
ü AV - 64 b/min.
Siguranta si tolerabilitate
Agentia Europeana a Medicamentelor: revizuirea profilului de siguranta
Ø Beneficiile tratamentului depasesc riscurile
Ø Este contraindicat la pacienti cu: boala Parkinson, tulburari extrapiramidale si
insuficienta renala severa
Ø Se reduce doza la 1 cp pe zi la pacientii varstnici si cu insuficienta renala moderata
1. European Medicines Agency Science Medicines Health. Questions and answers on the review of medicines containing
trimetazidine. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Trimetazidine_31/WC500129195.pdf. Accessed June 22, 2012; 2. Rezumatul
caracteristicilor produsului; 3. Ferrari et al. Lancet 2020; August 30, 2020; https://doi.org/10.1016/S0140-6736(20)3179
pentru pacientii cu boala cardiaca ischemica
1. Detry JM et al. Brit J Clin Pharmacol. 1994;37:279-288; 2. Peng S et al. Int J Cardiol. 2014;177:780-785; 3. Kunadian et al. European Heart Journal. 2020; 0: 1–21; 4. European Medicines
Agency Science Medicines Health. Questions and answers on the review of medicines containing
trimetazidine. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Trimetazidine_31/WC500129195.pdf. Accessed June 22, 2012; 5. Rezumatul
caracteristicilor produsului.